We are weaving a new tapestry for healthcare with the intertwining threads of biology, information technology, and the sleeping giant of consumer power. This is just the beginning.

Marcia A. Kean Chairman, Strategic Initiatives

Highlights

  • Frequent speaker at industry conferences
  • Editor of 3 editions of The Case for Personalized Medicine, the signature document of the Personalized Medicine Coalition
  • Originator of The Age of Personalized Medicine website
  • Counsellor to PhRMA, PMC, National Cancer Institute, Accelerated Cure Project for MS, etc.
  • Member, Advisory Committee for the Harvard Partners Personalized Medicine Conference
  • Recipient, Distinguished Service Award, Personalized Medicine Coalition, 2006

Marcia Kean has been involved in the transformative side of biomedicine for 30+ years, working closely with scientific pioneers in biopharma, academe and government. She has led Feinstein Kean’s presence in life sciences since the firm’s inception 25 years ago, including her tenure from 2002 to 2011 as the CEO.

In the first two decades of the biotech industry, she partnered with dozens of CEOs of start-up firms to build value for their companies by shaping their visibility and credibility.

Soon after the Mapping of the Human Genome, Marcia established the nation’s first Molecular Medicine communications practice. She was among an early-adopter group seeking to introduce molecular medicine to the world, while she played a key role in the establishment and development of the Personalized Medicine Coalition. She has led Feinstein Kean’s presence in this field, serving on government panels and collaborating with scientists at Harvard, Duke, UCSF and elsewhere to define and overcome obstacles to adoption. She is also deeply embedded in the field of cancer informatics, and is serving on the Advisory Committee of the Institute of Medicine’s Cancer Informatics Workshop and as a speaker at that event.

Under Marcia’s leadership, Feinstein Kean is proud to be co-hosting a Cancer Policy Conference in 2012, jointly with the Personalized Medicine Coalition and the American Association for Cancer Research.